Glutamate-rich protein (GLURP) (GLURP)

The Glutamate-rich protein (GLURP) is a high-molecular-weight antigen expressed by Plasmodium falciparum across multiple stages of its life cycle, including the surface of sporozoites, the parasitophorous vacuole of liver stages, and the surface of infected erythrocytes [1, 4]. The R0 region specifically refers to the N-terminal non-repeat domain of the protein, which has been identified as a primary target for protective antibodies in individuals with naturally acquired immunity to malaria [3, 4]. These antibodies are thought to act primarily through Antibody-Dependent Cellular Inhibition (ADCI), a mechanism where IgG binds to the parasite antigen and subsequently activates monocytes to release soluble factors that inhibit parasite growth [2, 3]. GLURP R0 is a key component of several malaria vaccine candidates, most notably the GMZ2 fusion protein, which combines R0 with the C-terminal region of Merozoite Surface Protein 3 (MSP3) [2]. Clinical trials have demonstrated that vaccines targeting this region can induce high titers of functional antibodies, although achieving long-lasting sterile immunity remains a significant therapeutic challenge [2, 4]. The relative conservation of the R0 region across different parasite strains makes it an attractive target for a blood-stage malaria vaccine [4].

Other names

Glutamate-rich proteinGLURP R0P. falciparum GLURPPF3D7_1035300

Induction of protective antibodies that mediate Antibody-Dependent Cellular Inhibition (ADCI) against asexual blood-stage parasites [2, 3].